Keywords: Cancer, Metabolism, Molecular Imaging, Preclinical, Ewing sarcoma, pediatric cancer
Motivation: Chemo resistance in Ewing sarcoma (EWS) poses a significant hurdle, especially considering the unclear role of the SLFN11 gene. Uninvestigated metabolic dependencies call for an in-depth exploration to improve treatment effectiveness.
Goal(s): This research endeavors to connect metabolic changes in EWS with SLFN11 expression, aiming to identify diagnostic markers that could provide mechanistic insights into therapy design.
Approach: Our study integrates metabolomics, transcriptomics, in-vitro nuclear magnetic resonance (NMR), and preclinical magnetic resonance spectroscopy (1H MRS) to examine how SLFN11 influences chemoresistance in EWS, ultimately paving way for metabolism-driven treatments.
Results: We found significantly increased glutamine uptake in SLFN-/- EWS cells compared to WT.
Impact: Using 1H-MRS, we show that SLFN11 loss increases EWS reliance on glutamine, is different than conventional glutamine metabolism typically observed in other cancers.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords